ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million. On January 26, the company announced it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with Chibret International, a prominent Asian ophthalmic company, to commercialize the product in Vietnam. ZHAOKE OPHTH-B has granted AFT and Chibret exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Chibret become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential treatment for correcting presbyopia-induced loss of near vision and is a core asset licensed by the company from its partner Tenpoint Therapeutics, Ltd. (Tenpoint).